Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Preventing Accumulation of Senescent Cells Reverses Adverse Signs of Aging

By LabMedica International staff writers
Posted on 15 Jan 2019
Researchers working with mouse models have shown that some of the less desirable signs of aging, such as chronic inflammation and reduced function of some organs, could be reversed by treatment to reduce the number of senescent cells that have accumulated in the animal.

Senescent cells are aged or damaged cells that accumulate in tissues in advanced age. More...
They no longer are able to perform their normal roles and interfere with the functioning of the tissue in which they accumulate. Elimination of senescent cells is considered to be a promising therapeutic approach.

The extent of immune-system involvement in regulating age-related accumulation of senescent cells, and its consequences, are unknown. To evaluate the role of the immune system in the aging process, investigators at the Weizmann Institute of Science (Rehovot, Israel) worked with Prf1−/− mice with impaired cell cytotoxicity, which suffered from chronic inflammation, and with progeroid (progeroid means "resembling premature aging") mice with impaired cell cytotoxicity that promoted senescent-cell accumulation and shortened lifespan.

The investigators reported in the December 21, 2018, online edition of the journal Nature Communications that Prf1−/− mice with impaired cell cytotoxicity exhibited both higher senescent cell tissue burden and chronic inflammation. They suffered from multiple age-related disorders and lower survival. The accumulation of senescent cells in these Prf1−/− mice was accompanied by a progressive state of chronic inflammation, followed by increased tissue fibrosis and other types of tissue damage, as well as compromised organ functionality. The poor health of old Prf1−/− mice was associated with fitness reduction, weight loss, kyphosis (abnormally excessive convex curvature of the spine), older appearance, and shorter lifespan than that of wild type controls.

The investigators reported that elimination of senescent cells from old Prf1−/− mice could be achieved by pharmacological inhibitors of the BCL-2 family of proteins, such as ABT-737. First developed for potential cancer chemotherapy, ABT-737 was subsequently identified as a senolytic (a drug that selectively induces cell death in senescent cells). This pharmacological approach attenuated age-related phenotypes and gene expression profile in Prf1−/− mice. Furthermore, implementation of this approach on Prf1−/− progeroid mice increased median lifespan of these animals.

These findings shed new light on mechanisms governing senescent-cell presence in aging, and could motivate new strategies for regenerative medicine.

Related Links:
Weizmann Institute of Science


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.